| Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity J Van Ryn, J Stangier, S Haertter, KH Liesenfeld, W Wienen, M Feuring, ... Thrombosis and haemostasis 103 (06), 1116-1127, 2010 | 1855 | 2010 |
| Pharmacokinetics of selective serotonin reuptake inhibitors C Hiemke, S Härtter Pharmacology & therapeutics 85 (1), 11-28, 2000 | 1015 | 2000 |
| The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY … PA Reilly, T Lehr, S Haertter, SJ Connolly, S Yusuf, JW Eikelboom, ... Journal of the American College of Cardiology 63 (4), 321-328, 2014 | 969 | 2014 |
| Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial KH Liesenfeld, T Lehr, C Dansirikul, PA Reilly, SJ Connolly, ... Journal of Thrombosis and Haemostasis 9 (11), 2168-2175, 2011 | 383 | 2011 |
| A review of the receptor-binding and pharmacokinetic properties of dopamine agonists T Kvernmo, S Härtter, E Burger Clinical therapeutics 28 (8), 1065-1078, 2006 | 332 | 2006 |
| Genetic determinants of dabigatran plasma levels and their relation to bleeding G Paré, N Eriksson, T Lehr, S Connolly, J Eikelboom, MD Ezekowitz, ... Circulation 127 (13), 1404-1412, 2013 | 323 | 2013 |
| CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine MEE Shams, B Arneth, C Hiemke, A Dragicevic, MJ Müller, R Kaiser, ... Journal of clinical pharmacy and therapeutics 31 (5), 493-502, 2006 | 300 | 2006 |
| Effective elimination of dabigatran by haemodialysis D Khadzhynov, F Wagner, S Formella, E Wiegert, V Moschetti, T Slowinski, ... Thrombosis and haemostasis 109 (04), 596-605, 2013 | 252 | 2013 |
| A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral … F Van de Werf, M Brueckmann, SJ Connolly, J Friedman, CB Granger, ... American heart journal 163 (6), 931-937. e1, 2012 | 238 | 2012 |
| Elevated levels of clozapine in serum after addition of fluvoxamine C Hiemke, H Weigmann, S HÄRTTER, N Dahmen, H Wetzel, H MÜLLER Journal of clinical psychopharmacology 14 (4), 279-280, 1994 | 228 | 1994 |
| Oral bioavailability of dabigatran etexilate (Pradaxa®) after co‐medication with verapamil in healthy subjects S Härtter, R Sennewald, G Nehmiz, P Reilly British journal of clinical pharmacology 75 (4), 1053-1062, 2013 | 198 | 2013 |
| Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates A Abou El Ela, S Härtter, U Schmitt, C Hiemke, H Spahn-Langguth, ... Journal of Pharmacy and Pharmacology 56 (8), 967-975, 2004 | 181 | 2004 |
| Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin S Härtter, M Koenen‐Bergmann, A Sharma, G Nehmiz, U Lemke, ... British journal of clinical pharmacology 74 (3), 490-500, 2012 | 151 | 2012 |
| Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin S Härtter, X Wang, H Weigmann, T Friedberg, M Arand, F Oesch, ... Journal of clinical psychopharmacology 21 (2), 167-174, 2001 | 133 | 2001 |
| Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection J Sachse, J Köller, S Härtter, C Hiemke Journal of Chromatography B 830 (2), 342-348, 2006 | 130 | 2006 |
| Increased bioavailability of oral melatonin after fluvoxamine coadministration S Härtter, M Grözinger, H Weigmann, J Röschke, C Hiemke Clinical Pharmacology & Therapeutics 67 (1), 1-6, 2000 | 126 | 2000 |
| Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. A Szegedi, H Wetzel, M Leal, S Härtter, C Hiemke The Journal of clinical psychiatry 57 (6), 257-264, 1996 | 124 | 1996 |
| The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia G Gründer, C Landvogt, I Vernaleken, HG Buchholz, J Ondracek, ... Neuropsychopharmacology 31 (5), 1027-1035, 2006 | 117 | 2006 |
| Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation T Lehr, S Haertter, KH Liesenfeld, A Staab, A Clemens, PA Reilly, ... The Journal of Clinical Pharmacology 52 (9), 1373-1378, 2012 | 115 | 2012 |
| Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service H Weigmann, S Gerek, A Zeisig, M Müller, S Härtter, C Hiemke Therapeutic drug monitoring 23 (4), 410-413, 2001 | 103 | 2001 |
Christoph HiemkeUniversity Medical Center MainzVerified email at uni-mainz.de
